Cabergoline,
does it really help with Shortened post-ejaculatory refractory period and multiple orgasms in healthy men?
research showsCabergoline receives C with 40 points. The only direct evidence in healthy men is one single-blind placebo-controlled crossover study of ten participants, in which a single 0.5-mg dose improved subjective ratings of sexual drive, function, and the refractory period. No large trial has confirmed an objectively shorter refractory time, and no human trial directly measuring the number or success of multiple orgasms was found. A retrospective chart review of 131 men with orgasmic disorder reported subjective improvement in 66.4%, but that population and endpoint differ from healthy men, refractory time, and multiple orgasms. The small human signal therefore earns the bottom of C under the subjective-only and tiny-sample limitation, while the multiple-orgasm subclaim is unknown.
ads claimA prolactin-lowering mechanism does not clinically guarantee deletion of recovery time or consecutive orgasms. The verified healthy-volunteer evidence is a ten-person single-dose study and cannot justify off-label self-treatment or long-term exposure.
Useful facts when choosing a product
- Cabergoline is an ergot-derived prescription dopamine agonist used mainly for hyperprolactinemia, and refractory-period shortening or multiple orgasms are not approved indications.
- Healthy-male evidence consists of a single-dose 0.5-mg study in ten men, leaving repeat dosing, long-term benefit, and appropriate candidates undefined.
- Nausea, headache, dizziness, and orthostatic hypotension can occur, and dopamine-agonist-related impulse-control or behavioral changes require attention.
- High cumulative exposure to ergot-derived dopamine agonists raises concern for cardiac valvulopathy and pleural or retroperitoneal fibrosis, making this unsuitable for sexual-function self-medication.
What the research actually shows
Krüger and colleagues used a balanced crossover design in ten healthy men receiving cabergoline 0.5 mg, prolactin-raising protirelin, or placebo, then assessed sexual drive, arousal, orgasm, and the refractory period with psychometric measures after erotic film and masturbation. Cabergoline lowered prolactin and improved sexual-function scores and positive perception of the refractory period, but did not time recovery or observe multiple orgasms. A single-andrology-clinic retrospective analysis by Hollander and colleagues found subjective improvement in 66.4% of 131 men treated for delayed orgasm or anorgasmia, without randomization or a control group. No verifiable clinical study directly evaluating multiple orgasms in healthy men was found.
Why this is classified as C (40)
A ten-person crossover study provides a subjective refractory-period and sexual-function signal, but there is no objective timing, replicated independent trial, or direct multiple-orgasm endpoint. An indirect retrospective orgasmic-disorder series does not overcome the subjective-only ceiling and severe limitations, yielding C with 40 points. Valvular, fibrotic, hypotensive, and impulse-control risks remain separate safety issues.
Counterpoint. Delayed orgasm and anorgasmia can arise from medicines, neurologic or endocrine disease, and psychological or relationship factors; cause assessment comes first, and cabergoline is not an established standard sexual-function drug.
Rejudgment record. New verdict — Accepted a subjective refractory-period and sexual-function signal from a single-blind placebo-controlled crossover study in ten healthy men, but applied the subjective-only and severe-limitation ceiling because objective refractory time, replicated independent trials, and a direct multiple-orgasm endpoint are absent and the retrospective orgasmic-disorder study is indirect
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Shortened post-ejaculatory refractory period in healthy men | C | A ten-person crossover study improved subjective perception but did not measure objective refractory time, providing only a low-C signal. |
| Multiple orgasms in healthy men | ? | No verifiable human efficacy study directly measuring the number or success of multiple orgasms was found. |
| Improved orgasmic function in men with delayed orgasm or anorgasmia | C | A retrospective 131-person series provides a subjective improvement signal but lacks randomization and a comparator. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Krüger THC et al. 2003 | Single-blind placebo- and active-controlled balanced crossover physiology study | 10 | Academic physiology research with no industry support reported | Prolactin and psychometric measures of drive, arousal, orgasm, and refractory period | Cabergoline 0.5 mg lowered prolactin and improved sexual function and positive perception of the refractory period, but did not measure objective time or multiple orgasms. | Only direct preliminary evidence in healthy men |
| Hollander AB et al. 2016 | Single-andrology-clinic retrospective pilot chart review | 131 | No external funding reported | Subjective improvement in orgasmic function | Eighty-seven men, 66.4%, reported improvement, but there was no comparator or randomization and evidence was indirect for healthy men's refractory period. | Indirect very-low-certainty supporting evidence |
| De Vecchis R et al. 2013 | Systematic review and meta-analysis of observational cabergoline and valvular-regurgitation studies | 7 | No industry funding reported | Cardiac valvular regurgitation | Valvular regurgitation increased strongly at Parkinson disease exposure, while mild-to-moderate tricuspid regurgitation increased at lower hyperprolactinemia exposure. | Cumulative-exposure safety context separated from efficacy |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-20).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] Cabergoline x shorter post-ejaculatory refractory period and multiple orgasms in healthy men — Evidence Grade C·40. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/cabergoline-healthy-men-refractory-period-multiple-orgasms/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.